Previous Article | Next Article ![]()
Journal of Virology, July 2007, p. 6798-6806, Vol. 81, No. 13
0022-538X/07/$08.00+0 doi:10.1128/JVI.02840-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Department of Virology II, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashi-murayama, Tokyo 208-0011, Japan,1 Center for Pathogen Genomics, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashi-murayama, Tokyo 208-0011, Japan,2 Division of Biosafety Control and Research, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku-ku, Tokyo 162-8640, Japan,3 Department of Veterinary Microbiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan4
Received 22 December 2006/ Accepted 11 April 2007
|
|
|---|
|
|
|---|
Calicivirus is a nonenveloped virus, and its genome is a linear, polyadenylated, positive-sense single-stranded RNA of about 7.3 to 8.3 kb with either two or three open reading frames (ORFs) (9). Calicivirus ORF1 encodes a polyprotein that contains amino acid motifs including 2C-like nucleoside triphosphatase (NTPase), VPg, 3C-like protease, and 3D-like RNA-dependent RNA polymerase (polymerase) (11, 25). In Sapovirus and Lagovirus, the structural protein VP1 is encoded in ORF1, whereas this protein is encoded in a separate ORF (ORF2) in Vesivirus and Norovirus. Cotranslational proteolytic processing of the ORF1 polyprotein is a common feature in the caliciviruses and is performed with the 3C-like protease encoded in ORF1 (11). The calicivirus 3C-like protease cleaves after the glutamic acid (E) or glutamine (Q) residue of the specific site in the polyprotein (2, 4, 14, 20, 21, 30, 32, 33, 35, 39). The protease itself is released by an autocatalytic cleavage in NoV (1, 2, 8, 15, 21, 32, 39) and RHDV (19, 25, 44), whereas cleavage between the protease and polymerase does not occur in FCV (7, 12, 40, 43) or SaV (7, 28-30).
The critical role of Cys in the calicivirus 3C-like protease motif GDCG in the cleavage activity in NoV and RHDV has been determined previously (4, 15, 20, 32, 34). In addition, the active-site residues of the 3C-like proteases of the NoV Chiba virus strain and the RHDV FRG strain have been identified by site-directed mutagenesis (5, 14, 36, 46). Recently, the X-ray crystal structures of the two 3C-like proteases of NoV (Chiba and Norwalk strains) were determined (27, 46). In contrast, although site-directed mutagenesis of the 3C-like proteases of the SaV Mc10 and FCV Urbana strains showed that C in the GDCG motif is crucial for the proteolytic processing activity (28-30), the remaining amino acids that are important for the activity have not been identified.
The aim of this study was to identify and structurally characterize the functional protease domains and the amino acid residues critical to the activities in SaV and FCV. For this purpose, an in vitro coupled transcription-translation analysis was performed with full-length or C-terminally truncated forms of the ORF1 polyprotein with or without amino acid mutations in the protease domain. In addition, three-dimensional (3-D) structural models of the 3C-like protease domains of the SaV Mc10, FCV F4, and RHDV FRG strains were constructed and compared with the X-ray crystal structure of the 3C-like protease of the NoV Chiba strain (27).
|
|
|---|
Preparation of FCV F4. Crandell-Rees feline kidney cells (JCRB9035; Health Science Research Resources Bank, Japan) were grown in a 150-cm2 flask containing Eagle's minimum essential medium (Sigma-Aldrich, St. Louis, MO) with 5% calf serum (JRH Bioscience Corp., Tokyo, Japan) and virus production serum-free medium with L-glutamine (Invitrogen, Carlsbad, CA). Approximately 104 PFU of the virus was added to a monolayer of Crandell-Rees feline kidney cells containing 10 ml of culture medium. The cells were incubated for 3 days at 37°C and were harvested when the cytopathic effect had reached 90%. After three cycles of freezing and thawing, the cell debris were removed by centrifugation and the supernatant was stored at 30°C until use.
Full-length cDNA clones. A plasmid designated pUC19/SaV Mc10 full-length containing a full-length SaV Mc10 genome with the T7 promoter, as well as a plasmid designated as pUC19/SaV Mc10 full-C1171A/ORF1 encoding a 1169GDCG1172-to-GDAG mutation in the protease, were expressed as previously described (29).
The FCV F4 genomic RNA was purified from the culture medium by the QIAamp viral RNA mini kit (QIAGEN, Hilden, Germany). FCV F4 cDNA was synthesized as previously described (16). The 5' fragment corresponding to nucleotides (nt) 1 to 3785 was amplified with the sense primer 5'-GTAAAAGAAATTTGAGACAATGTCTC-3' and the antisense primer 5'-GTTTACAAACTAATCCCTTGTAGC-3'. The middle fragment corresponding to nt 2990 to 6971 was amplified with the sense primer 5'-AATGCCAACAGAAAGCTTGA-3' and the antisense primer 5'-AGCACGCTAATGCGCACTAC-3'. The 3' fragment corresponding to nt 6952 to 7681 was amplified with the sense primer 5'-GTAGTGCGCATTAGCGTGC-3' and the antisense primer 5'-CCCTGGGGTTAGACGCAAATGC-3'. These three fragments were cloned into the pCR-BluntII-Topo vector (Invitrogen), and the resulting constructs were designated FCV F4 5'/Topo, FCV F4 middle/Topo, and FCV F4 3'/Topo, respectively. Several amplification and cloning steps were performed to yield a full-length construct with a T7 RNA polymerase promoter at the 5' end and both a hepatitis D virus (HDV) ribozyme and a T7 terminator at the 3' end, as described previously (15). To add the HDV ribozyme and the T7 terminator at the 3' end of the FCV F4 genome, the region from nt 6952 to 7681 was reamplified from the clone 3'/Topo with a sense primer (5'-GTAGTGCGCATTAGCGTGC-3') and an antisense primer (5'-GAGGTGGAGATGCCATGCCGACCCT30CCCTGGGGTTAGACGCAAATGC-3'). HDV ribozyme and T7 terminator sequences were amplified from the pT7HCV09Luc plasmid (45) with a sense primer (5'-GGGTCGGCATGGCATCTCCACCTC-3') and an antisense primer (5'-GAACTAGTGGATCCGAGCTCAGATCTCCTTTCAGCAAAAAACCCCTCAA G-3') that included a BglII site (underlined) and a SacI site (double underlined). These DNA fragments were joined by a primerless PCR as previously described (15), and the amplified fragment corresponding to nt 6952 to 7681 was purified from the gel by using the QIAGel extraction kit (QIAGEN). This DNA fragment was designated FCV F4 6952-7681 polyA-Rz-T7 term. Following these experiments, the FCV F4 region from nt 2990 to 6971 was reamplified with the sense primer 5'-AATGCCAACAGAAAGCTTGA-3' and the antisense primer 5'-AGCACGCTAATGCGCACTAC-3'. The amplified DNA fragment was joined with 6952-7681 polyA-Rz-T7 term in a primerless PCR. The joined amplified fragment was purified and cloned into the pCR-BluntII-Topo vector, and the construct was designated FCV F4 2990-7681 polyA-Rz-T7 term/Topo. This plasmid was digested with KpnI and SacI (New England Biolabs, Beverly, MA), and the insert was cloned into a pUC19 vector (Toyobo, Osaka, Japan) which was previously digested with KpnI and SacI. The resultant plasmid was designated FCV F4 middle + 3' polyA-Rz-T7 term/pUC19. Finally, the FCV F4 5' region corresponding to nt 1 to 3780 was reamplified from FCV F4 5'/Topo with a sense primer (5'-CAGGGGCCCGTCGACCTGGTAATACGACTCACTATAGTAAAAGAAATTTGAGACAATGTC-3') that included a SalI site (underlined) and a T7 RNA polymerase promoter sequence (bold) and an antisense primer (5'-TTGGGCCATGCAGGTGAGCG-3'). The amplified DNA was purified and digested with SalI and KpnI (New England Biolabs) and cloned into SalI- and KpnI-digested middle + 3' polyA-Rz-T7 term/pUC19. The resultant plasmid was designated FCV F4 T7-GG full-length-Rz-T7 term/pUC19 ver2 (pUC19/FCV F4 full-length). Sequence analysis confirmed that the cloned genome corresponded to the consensus sequence of FCV F4 (GenBank accession number D31836), with the exception of a silent mutation (T to C) at the nucleotide position 4075.
Site-directed mutagenesis. Site-directed mutagenesis was performed using the GeneTailor site-directed mutagenesis system (Invitrogen), with pUC19/SaV Mc10 full-length (29) and pUC19/FCV F4 full-length as the templates. The site-directed mutagenesis primers are listed in Table 1. The resulting nine SaV Mc10 full-length mutant cDNA clones were designated as follows: pUC19/SaV Mc10 full-H1069A/ORF1 (where the H at amino acid [aa] residue 1069 in the ORF1 product is changed to A), pUC19/SaV Mc10 full-H1075A/ORF1, pUC19/SaV Mc10 full-H1086A/ORF1, pUC19/SaV Mc10 full-E1107A/ORF1, pUC19/SaV Mc10 full-H1120A/ORF1, pUC19/SaV Mc10 full-H1136A/ORF1, pUC19/SaV Mc10 full-E1143A/ORF1, pUC19/SaV Mc10 full-E1147A/ORF1, and pUC19/SaV Mc10 full-H1186A/ORF1. Similarly, 12 FCV F4 full-length mutant cDNA clones were constructed: pUC19/FCV F4 full-H1079A/ORF1, pUC19/FCV F4 full-H1093A/ORF1, pUC19/FCV F4 full-H1099A/ORF1, pUC19/FCV F4 full-H1102A/ORF1, pUC19/FCV F4 full-H1110A/ORF1, pUC19/FCV F4 full-E1121A/ORF1, pUC19/FCV F4 full-D1125A/ORF1, pUC19/FCV F4 full-E1131A/ORF1, pUC19/FCV F4 full-D1155A/ORF1, pUC19/FCV F4 full-E1164A/ORF1, pUC19/FCV F4 full-C1193A/ORF1, and pUC19/FCV F4 full-H1208A/ORF1. All of these full-length clones were verified by sequencing analysis to confirm that there were no additional mutations.
|
View this table: [in a new window] |
TABLE 1. Oligonucleotides used for the site-directed mutagenesis
|
|
View this table: [in a new window] |
TABLE 2. PCR primers to prepare templates for in vitro transcription-translation
|
Nucleotide and amino acid sequence analyses. Nucleotide sequence analysis was performed with the BigDye Terminator (version 3.1) cycle sequencing ready reaction kit (Applied Biosystems, Tokyo, Japan) and an automated sequencer (genetic analyzer 3130; Applied Biosystems). Nucleotide sequences were assembled with the program Sequencher, version 4.2.2 (Gene Codes Corp., Ann Arbor, MI). Nucleotide and amino acid sequences were analyzed with GENETYX Mac software, version 12.2.6 (Genetyx Corp., Tokyo, Japan).
Molecular modeling of SaV, FCV, and RHDV 3C-like proteases. The crystal structure of the NoV 3C-like protease (Protein Data Bank [PDB] code, 1WQS) (27) at a resolution of 2.80 Å was used as the template for the molecular modeling of the SaV, FCV, and RHDV 3C-like proteases. To minimize misalignments of the target and template sequences, multiple-sequence alignments of 3C cysteine proteases, including rhinovirus 3C protease (PDB code, 1CQQ) (23), poliovirus 3C protease (PDB code, 1L1N) (26), and hepatitis A virus 3C protease (PDB code, 1QA7) (3), were used. The alignments were generated using MOE-Align in the Molecular Operating Environment (MOE) package (Chemical Computing Group, Inc., Montreal, Quebec, Canada). 3-D models of SaV Mc10, FCV F4, and RHDV FRG 3C-like proteases were constructed by the homology modeling technique using MOE-Homology in the MOE package as described previously (17, 18). The 3-D structures were thermodynamically optimized by energy minimization with the MOE package and an AMBER99 force field (31). A physically unacceptable local structure of the optimized 3-D model was further refined on the basis of Ramachandran plot evaluation using the MOE package. The quality of the models was assessed using the 3-D-structure evaluation program Verify3D (6, 47).
Strains for amino acid sequence alignments. The 16 SaV strains used for amino acid sequence alignments are as follows, with the nucleotide sequence accession numbers for the corresponding nucleotide regions given in parentheses: Mc114 (AY237422), Manchester (X86560), Dresden (AY694184), N21 (AY237423), Nongkhai50 (AY646853), Chantaburi74 (AY646854), Mc10 (AY237420), Bristol (AJ249939), C12 (AY603425), Mc2 (AY237419), SK15 (AY646855), PEC Cowden (AF182760), PEC LL14 (NC 000940), Ehime1107 (DQ058829), Sw278 (DQ125333), and NK24 (AY646856). The 13 FCV strains used for amino acid sequence alignments are as follows, with the nucleotide sequence accession numbers for the corresponding nucleotide regions given in parentheses: F4 (D31836), F65 (AF109465), 2024 (AF479590), Urbana (L40021), F9 (M86379), CFI/68 (U13992), DD/2006/GE (DQ424892), UTCV-NH1 (AY560113), UTCV-NH2 (AY560114), UTCV-NH3 (AY560115), UTCV-H1 (AY560116), UTCV-H2 (AY560117), and USDA (AY560118).
|
|
|---|
![]() View larger version (29K): [in a new window] |
FIG. 1. Identification of the C terminus of the SaV Mc10 protease. (A) Proteolytic cleavage map of the SaV Mc10 ORF1 polyprotein and the processing intermediates (30). (B) SDS-PAGE of in vitro 35S-labeled wild-type (Prow) and C1171A mutant (Promut) forms of the entire ORF1 polyprotein (aa 1 to 2278) and 15 C-terminally truncated polyproteins corresponding to aa 1 to 1246, 1 to 1240, 1 to 1234, 1 to 1229, 1 to 1223, 1 to 1218, 1 to 1212, 1 to 1206, 1 to 1205, 1 to 1204, 1 to 1203, 1 to 1202, 1 to 1201, 1 to 1200, and 1 to 1194. The protein bands corresponding to either the Prow or Promut form of the entire ORF1 polyprotein are indicated by filled and open arrowheads, respectively. The molecular sizes of viral proteins are shown on the right, and size markers are shown on the left. Asterisks indicate two C-terminally truncated forms, corresponding to aa 1 to 1200 and 1 to 1194, which show affected protease activity. Products of approximately 15 to 20 kDa would be the truncated Pro-Pol, released from the truncated ORF1 polyprotein. A 60-kDa product of the C-terminally truncated form corresponding to aa 1 to 1200 was identified as p32-VPg-truncated Pro-Pol.
|
Identification of the active-site residues of the SaV Mc10 3C-like protease. SaV Mc10 3C-like protease cleaves after the E or Q residue of the specific site in the ORF1 polyprotein (Fig. 1), and the C1171 in the GDCG motif was shown to be critical to the protease activity (28-30). Furthermore, the functional SaV Mc10 protease was found to be similar in size to those of RHDV and NoV. These results suggested that the catalytic amino acid residues of the SaV Mc10 protease would also be similar to those of other caliciviruses. In RHDV and NoV, the amino acid residues critical to protease activity have been identified as H27, D44, C104, and H119 and H30, E54, C139, and H157, respectively, although it remains controversial whether or not E54 has a critical role in NoV protease activity (5, 14, 36, 46). The amino acid essential for the protease activity will definitely be conserved among all SaV strains (at least among human SaV strains) as it is in NoV and RHDV (36) (data not shown). Nine amino acid residues (H1069, H1075, H1086, E1107, H1120, H1136, E1143, E1147, and H1186) within the protease domain were selected based on the amino acid alignment of 14 human SaV strains, with one exception: D instead of E1147 in a human SaV NK24 strain (data not shown). These nine amino acid residues were changed to A by site-directed mutagenesis (Table 1), and nine mutant forms of the ORF1 polyprotein, the H1069A, H1075A, H1086A, E1107A, H1120A, H1136A, E1143A, E1147A, and H1186A forms, were expressed in an in vitro translation system. Two forms of the ORF1 polyprotein, the full-length Prow and Promut (C1171A) forms, were used as positive and negative controls, respectively (Fig. 2) (29, 30). Three mutant forms of the ORF1 polyprotein, the H1086A, E1107A, and H1186A forms, each produced a major 250-kDa product (Fig. 2), demonstrating that the proteolytic processing of the ORF1 polyprotein was completely blocked with these mutant forms. In contrast, the cleavage products of six mutant forms, the H1069A, H1075A, H1120A, H1136A, E1143A, and E1147A forms, were identical to those of Prow, although their cleavages were slightly affected (Fig. 2). From these results, we concluded that the amino acid residues critical to SaV Mc10 3C-like protease activity are H1086(31), E1107(52), C1171(116), and H1186(131). The first three of these would form the catalytic triad (general base, anion, and nucleophile, respectively), and the last one would correspond to part of the binding pocket as previously described for other calicivirus proteases (5, 27, 36, 46). Two amino acids, E1107 and H1186, essential to the SaV Mc10 protease activity are not conserved in porcine SaV; (i) E1107 in Mc10 is D in the PEC LL14 and Cowden strains, and (ii) H1186 in Mc10 is Y in the PEC LL14 strain, whereas H1186 is conserved in the PEC Cowden strain (data not shown).
![]() View larger version (39K): [in a new window] |
FIG. 2. Identification of the amino acid residues critical to SaV Mc10 protease activity. Shown are the results of SDS-PAGE of in vitro 35S-labeled wild-type (Prow) and C1171A mutant forms of the entire ORF1 polyprotein (aa 1 to 2278) and nine other mutant forms, the H1069A, H1075A, H1086A, E1107A, H1120A, H1136A, E1143A, E1147A, and H1186A polyproteins. The protein bands corresponding to either the Prow or C1171A form of the entire ORF1 polyprotein are indicated by filled and open arrowheads, respectively. The molecular sizes of viral proteins are shown on the right, and size markers are shown on the left. Asterisks indicate four mutant forms, the C1171A, H1086A, E1107A, and H1186A polyproteins, which display affected protease activity.
|
We generated two full-length cDNA clones, pUC19/FCV F4 full-length and pUC19/FCV F4 full-C1193A/ORF1, the latter of which encodes a 1191GDCG1194-to-GDAG mutation in the protease. The expression was carried out with both Prow and Promut (C1193A) forms of the protease, and the latter were used as a negative control for the proteolytic processing. Six major cleavage products, p30, p32, p39 (NTPase), p43 (p30-VPg), p76 (Pro-Pol), and p120 (p30-VPg-Pro-Pol), were detected when the Prow form corresponding to aa 1 to 1763 was expressed in an in vitro translation system (Fig. 3). These cleavage products were identical to those of the Urbana strain (40). A major 195-kDa product (p195) corresponding to the ORF1 polyprotein appeared when the Promut form was expressed (Fig. 3B), demonstrating that the C1193 is critical to the FCV F4 3C-like protease activity, consistent with a previous report (42).
![]() View larger version (33K): [in a new window] |
FIG. 3. Identification of the C terminus of the FCV F4 protease. (A) Proteolytic cleavage map of the FCV F4 ORF1 polyprotein and processing intermediates. The locations and designations of the proteins are adopted from the studies by Sosnovtsev et al. (40). (B) SDS-PAGE of in vitro 35S-labeled wild-type (Prow) and C1193A mutant (Promut) forms of the entire ORF1 polyprotein (aa 1 to 1763) and 10 C-terminally truncated polyproteins corresponding to aa 1 to 1419, 1 to 1345, 1 to 1267, 1 to 1245, 1 to 1240, 1 to 1235, 1 to 1230, 1 to 1225, 1 to 1224, and 1 to 1223. The protein bands corresponding to either the Prow or Promut form of the entire ORF1 polyprotein are indicated by filled and open arrowheads, respectively. The molecular sizes of viral proteins are shown on the right, and size markers are shown on the left. Asterisks indicate two C-terminally truncated forms, corresponding to aa 1 to 1224 and 1 to 1223, which display affected protease activity. Products of approximately 15 to 25 kDa would be the truncated Pro-Pol released from the truncated ORF1 polyprotein.
|
Identification of the active sites of the FCV F4 3C-like protease. The FCV 3C-like protease cleaves after the E residues of the specific site in the ORF1 polyprotein (Fig. 3A), and the C in the GDCG motif is critical to the protease activity (40-42). The functional FCV F4 protease is similar in size to those of SaV, RHDV, and NoV. Thus, the catalytic amino acid residues of the FCV protease would also be similar to those of SaV, RHDV, and NoV. Therefore, 11 amino acid residues (H1079, H1093, H1099, H1102, H1110, E1121, D1125, E1131, D1155, E1164, and H1208) within the protease domain were selected and were changed to A by site-directed mutagenesis (Table 1).
Eleven mutant forms of the ORF1 polyprotein, the H1079A, H1093A, H1099A, H1102A, H1110A, E1121A, D1125A, E1131A, D1155A, E1164A, and H1208A forms, were expressed in an in vitro translation system. Two forms of ORF1 polyprotein, the full-length Prow and Promut (C1193A) forms, were used as positive and negative controls for the proteolytic processing (Fig. 4). H1110A did significantly affect the ORF1 polyprotein processing, whereas E1131A and H1208A affected the processing partially (Fig. 4). That is, (i) p195, the entire ORF1 polyprotein, was detected when the H1110A form was expressed, (ii) p30 disappeared and p155 (likely the stable intermediate of NTPase-p30-VPg-Pro-Pol) appeared when the E1131A form was expressed, and (iii) p195 and p155 (NTPase-p30-VPg-Pro-Pol) appeared whereas p43 (p30-VPg) and p30 disappeared when the H1208A form was expressed. Prolonged incubation for up to 16 h did not change the processing patterns of these templates (data not shown). In contrast, the proteolytic processing of the ORF1 polyprotein was barely affected when five mutant forms, the H1099A, H1102A, E1121A, D1125A, and D1155A forms, were expressed (Fig. 4). The p120 (p30-VPg-Pro-Pol) band disappeared when two mutant forms, the H1079A and H1093A forms, were expressed. However, the mutated amino acid residues in these forms are not critical to protease activity, because other cleavage products were produced normally. Therefore, this product would be a precursor intermediate. Combining these results, we concluded that the amino acid residues important to FCV F4 3C-like protease activity are H1110(39), E1131(60), C1193(122), and H1208(137). The former three amino acid residues would form the catalytic triad, and the last amino acid residue would correspond to a part of the binding pocket as discussed for other calicivirus proteases. A reverse genetics system has been reported for FCV (37, 38, 40), and it would be interesting to evaluate whether the E1131A and H1208A mutant forms are also important in vivo.
![]() View larger version (76K): [in a new window] |
FIG. 4. Identification of the amino acid residues critical to FCV F4 protease activity. Shown are the results of SDS-PAGE of in vitro 35S-labeled wild-type (Prow) and C1193A mutant forms of the entire ORF1 polyprotein (aa 1 to 1763) and 11 other mutant forms, the H1079A, H1093A, H1099A, H1102A, H1110A, E1121A, D1125A, E1131A, D1155A, E1164A, and H1208A polyproteins. The protein bands corresponding to either the Prow or C1193A form of the entire ORF1 polyprotein are indicated by filled and open arrowheads, respectively. The molecular sizes of viral proteins are shown on the right, and size markers are shown on the left. Asterisks indicate four mutant forms, the C1193A, H1110A, E1131A, and H1208A polyproteins, which show affected protease activity. The newly appearing product, p155, also marked with an asterisk, probably corresponds to NTPase-p30-VPg-Pro-Pol.
|
![]() View larger version (45K): [in a new window] |
FIG. 5. 3-D models of the calicivirus 3C-like proteases. (A to D) Structural models of calicivirus 3C-like protease domains of the SaV Mc10 (A), FCV F4 (B), and RHDV FRG (C) strains and crystal structure of the NoV Chiba strain protease (27) (D). (E) Superimposition of 3C-like protease structures of the SaV Mc10, FCV F4, RHDV FRG, and NoV Chiba strains. The models were constructed with a homology modeling technique by using programs in the MOE package. Ribbons represent the backbone of the 3C-like protease domain. Side chains of the catalytically important amino acids identified in this study are shown as cyan sticks (H), red sticks (D and E), yellow sticks (C), and green sticks (H).
|
Conclusions. The functional domains, amino acid residues critical to the proteolytic processing activity, and structural characteristics of SaV and FCV 3C-like proteases were identified. The molecular genetics study showed that the sizes and catalytically important amino acids of the SaV and FCV proteases are similar to those of RHDV and NoV proteases. The computer-assisted structural study strongly suggested that these amino acids are involved in the formation of a conserved catalytic surface of the calicivirus 3C-like protease. In this study, we studied both primary and 3-D structures of SaV and FCV proteases, which are mutually closely related subjects and should be understood in concert. In collaboration with other resources, the data obtained in this study will provide important bases to study the molecular function and inhibitors of calicivirus proteases.
This work was supported in part by grants for research on emerging and reemerging infectious diseases, as well as food safety, from the Ministry of Health, Labor, and Welfare of Japan and by a grant from the Japan Health Science Foundation for Research on Health Sciences Focusing on Drug Innovation.
Published ahead of print on 25 April 2007. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»